Roche Breast Cancer Drug Gets FDA Priority Review

2/8/2012 8:12:29 AM

Roche Holding AG Wednesday said the U.S. Food and Drug Administration has accepted the company's Biologics License Application for pertuzumab and granted Priority Review. MAIN FACTS: - The proposed indication is pertuzumab in combination with Herceptin (trastuzumab) and docetaxel chemotherapy for people with HER2-positive metastatic or locally recurrent, unresectable breast cancer, who have not received previous treatment or whose disease has relapsed after adjuvant therapy.

Source: http://www.biospace.com/news_story.aspx?StoryID=248854&full=1

tyler bray tyler bray san antonio weather austin box austin box the academy is the academy is